Literature DB >> 12135556

Catalytically active Dengue virus NS3 protease forms aggregates that are separable by size exclusion chromatography.

Tracy L Arakaki1, Ning-Xia Fang, David P Fairlie, Paul R Young, Jennifer L Martin.   

Abstract

An active form of the Dengue virus protease NS3 (CF40.Gly.NS3pro) was expressed in Escherichia coli. This construct consists of a critical 40 amino acid cofactor domain from NS2B fused to the N-terminal 184 amino acid protease domain of NS3 via a flexible, covalent linker (Gly(4)SerGly(4)). The recombinantly produced protein is soluble and has a hexa-histidine tag engineered at the N-terminus for ease of purification using metal affinity chromatography. However, the presence of lower molecular weight impurities after affinity chromatography indicated the need for additional purification steps. The consistent appearance of these impurities suggested that they may be the products of proteolysis and/or auto-proteolysis. The latter possibility was subsequently excluded by the observation of the same impurities in a purified, catalytically inactive form of the recombinant protease (CF40.Gly.NS3pro.SA). Further analysis indicated that these impurities may represent premature translation termination products. Regardless of their origin, they were shown to form various sized aggregates with full-length CF40.Gly.NS3pro that can be separated by size exclusion chromatography, yielding fractions of active protease of sufficient purity for crystallisation trials. The ultimate goal of these studies is to obtain a crystal structure of a catalytically active form of the Dengue virus NS3 protease for structure-based drug design.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135556     DOI: 10.1016/s1046-5928(02)00005-0

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  6 in total

1.  Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design.

Authors:  Rosa Ramírez; Rosabel Falcón; Alienys Izquierdo; Angélica García; Mayling Alvarez; Ana Beatriz Pérez; Yudira Soto; Mayra Muné; Emiliana Mandarano da Silva; Oney Ortega; Ronaldo Mohana-Borges; María G Guzmán
Journal:  Virus Genes       Date:  2014-05-23       Impact factor: 2.332

Review 2.  Functional interplay among the flavivirus NS3 protease, helicase, and cofactors.

Authors:  Kuohan Li; Wint Wint Phoo; Dahai Luo
Journal:  Virol Sin       Date:  2014-03-26       Impact factor: 4.327

3.  Enzymatic characterization of a trypsin-like serine protease encoded by the genome of cell fusing agent virus.

Authors:  Christophe N Peyrefitte; Boris A M Pastorino; Marc Grandadam; Dominique Rolland; Hugues J Tolou; Maël Bessaud
Journal:  Virus Genes       Date:  2006-12-02       Impact factor: 2.332

4.  Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay.

Authors:  Chi-Chen Yang; Yi-Chen Hsieh; Shiow-Ju Lee; Szu-Huei Wu; Ching-Len Liao; Chang-Huei Tsao; Yu-Sheng Chao; Jyh-Haur Chern; Chung-Pu Wu; Andrew Yueh
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

5.  Development and utility of an in vitro, fluorescence-based assay for the discovery of novel compounds against dengue 2 viral protease.

Authors:  Gianne Eduard L Ulanday; Kenta Okamoto; Kouichi Morita
Journal:  Trop Med Health       Date:  2016-08-10

Review 6.  Contemporary Strategies and Current Trends in Designing Antiviral Drugs against Dengue Fever via Targeting Host-Based Approaches.

Authors:  Foysal Ahammad; Tengku Rogayah Tengku Abd Rashid; Maizan Mohamed; Suriyea Tanbin; Fazia Adyani Ahmad Fuad
Journal:  Microorganisms       Date:  2019-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.